Methylprednisolone

Abstract

Posterior reversible encephalopathy: 2 case reports In a study, 2 patients were described who developed posterior reversible encephalopathy syndrome (PRES) during treatment with methylprednisolone for systemic lupus erythematosus (SLE) [route, frequency and duration of treatment to reaction onset not stated]. A 19-year-old woman developed posterior reversible encephalopathy during treatment with methylprednisolone for SLE. The woman, who had been diagnosed with SLE, presented with crampy abdominal pain for 1 week. Subsequently, she was diagnosed with lupus nephritis and mesenteric vasculitis. Therefore, she started receiving therapy with methylprednisolone pulse 1g. However, she developed recurrent seizures following first dose of methylprednisolone. Thus, she was diagnosed with of PRES attributed to methylprednisolone pulse therapy. A 35-year-old woman developed developed posterior reversible encephalopathy during treatment with methylprednisolone for SLE. The woman, who had been diagnosed with SLE, presented to hospital with generalised tonic-clonic seizures upon admission. Thereafter, she started receiving therapy with methylprednisolone pulse 1g. Subsequently, post first dose of methylprednisolone, she experienced sudden blurring of vision (left eye), which progressed to left monocular blindness. However, she was diagnosed with PRES attributed to methylprednisolone therapy. Both the female patients satisfactorily recovered following individualised immunosuppression regimens and strict BP control.